Ndakambokuudza Here Izvi, Jurassic Park, Jurassic Nyika Dhimoni, Sam neill
Sam Neill, mutambi we "Jurassic Park", akaonekwa kuti ane kenza yeropa
Kurume 2023: Chitsauko chekutanga chememoir yaSam Neill chingave chinokatyamadza kumunhu anga asina ruzivo nazvo. Zvinotanga zvinosetsa zvakakwana: shinda huru nezvemwanasikana wake Elena achibvunzwa nezve joko rababa vake ..
CAR T Cell therapy miedzo, miedzo yakawanda myeloma
Muedzo wekiriniki paCAR-T Cell kurapwa kune varwere vane BCMA/TACI-positive vakadzoka zvakare uye/kana refractory multiple myeloma.
Brief Summary: A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma Detailed Description: This is a single arm, open-label, si..
AZA-JMML-001, Nhoroondo ye Celgene Corporation, vechidiki myelomonocytic leukemia, NCT02447666, Vidaza
Azacitidine inotenderwa neFDA kune ichangobva kuongororwa pwere myelomonocytic leukemia
Chikumi 2022: FDA yakabvumidza mushonga weazacitidine (Vidaza, Celgene Corp.) wevana vachangobva kubatwa nejuvenile myelomonocytic leukemia (JMML). The pharmacokinetics, pharmacodynamics, chengetedzo, uye chiitiko che azacitidine p.
BCMA, CARVYKTI, ciltacabtagene autoleucel, immunomodulatory mumiririri, Janssen Biotech, proteasome inhibitor
Ciltacabtagene autoleucel inotenderwa kudzokororwa kana refractory akawanda myeloma
Kurume 2022: Mushure memitsara mina kana kupfuura yekutanga yekurapa, kusanganisira proteasome inhibitor (PI), immunomodulatory agent (IMiD), uye anti-CD38 monoclonal antibody, iyo Food and Drug Administration yakabvumidza ciltacabtagene kana.
Chidzidzo chinopa CAR T-Cell therapy inoshanda seyekutanga mutsara kurapwa kwepamusoro njodzi yakakura B-cell lymphoma
Kurume 2022: Yunivhesiti yeTexas MD Anderson Cancer Center vaongorori vakawana kuti axi-cel, autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), yakachengeteka uye inoshanda mutsara wekutanga kurapa kune varwere vane ..
Burkitt lymphoma, Burkitt-kufanana lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab pamwe nechemotherapy inotenderwa neFDA kune zviratidzo zvegomarara revana
Kurume 2022: Chikafu neDrug Administration yakabvumidza rituximab (Rituxan, Genentech, Inc.) pamwe chete nechemotherapy yeCD20-positive diffuse hombe B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
Amgen, carfilzomib, Darzalex Faspro, dexamethasone, Janssen Biotech, Kyprolis, akawanda myeloma
Darzalex faspro, kyprolis, uye dexamethasone inotenderwa neFDA kune akawanda myeloma.
Kurume 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) uye carfilzomib (Kyprolis, Amgen, Inc.) pamwe nedexamethasone zvakatenderwa neChikafu neDrug Administration kuvarwere vakuru vane relap.
Kushanda kweCAR T-Cell kurapa kurwisa njodzi yakakura yakakura B-Cell lymphoma
Zvita 2020: Yunivhesiti yeTexas MD Anderson Cancer Center vaongorori vakawana kuti axi-cel, autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, yakachengeteka uye inoshanda yekutanga-mutsara kurapa kune varwere vane ...
Asciminib, chisingaperi myeloid leukemia, Novartis AG, Ph+ CML, Philadelphia chromosome, Scemblix
Asciminib inotenderwa kuPhiladelphia chromosome-positive chronic myeloid leukemia
Mbudzi 2021: Asciminib (Scemblix, Novartis AG) yakapihwa yakakurumidza kubvumidzwa neFood and Drug Administration kune varwere vane Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) muchikamu chisingaperi (CP) vaive nepr.
bhora, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel inotenderwa neFDA kuti idzoke kana refractory B-cell precursor acute lymphoblastic leukemia.
Gumiguru 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) yakabvumidzwa neFood and Drug Administration yevarwere vakuru vane kudzoka kana kuramba B-cell precursor acute lymphoblastic leukemia (ALL). Mu..